Currently Viewing:
Newsroom
Currently Reading
FDA Approves of Darzalex Combination for Multiple Myeloma
June 23, 2017 – Alison Rodriguez
Dr Yousuf Zafar of Duke Cancer Institute Joins The Samfund's Advisory Council
June 22, 2017 – AJMC Staff
FDA Approves Baxdela for Skin Infections
June 22, 2017 – Alison Rodriguez
What We're Reading: ACA Insurers File; Missouri Sues Opioid Manufacturers; Mylan's EpiPen Deals
June 22, 2017 – AJMC Staff
Mutation Burden and PD-L1 Expression Influence Response to Nivolumab in NSCLC
June 22, 2017 – Christina Mattina
Developing a Creative Strategy to Present the Value of Oncology Drugs
June 22, 2017 – Surabhi Dangi-Garimella, PhD
FDA Panel Gives Liraglutide Nod for CV Indication
June 21, 2017 – Mary Caffrey
Research Warns Patients of Drug-Drug and Herb-Drug Interactions
June 21, 2017 – Christina Mattina
Asian Women Face Greater Barriers to Follow-up Care on Abnormal Mammogram
June 20, 2017 – Surabhi Dangi-Garimella, PhD

FDA Approves of Darzalex Combination for Multiple Myeloma

Alison Rodriguez
The FDA has approved the use of Janssen Biotech, Incís immunotherapy Darzalex in combination with pomalidomide and dexamethasone. Darzalex is used to treat multiple myeloma patients who have previously received at least 2 therapies with lenalidomide and a proteasome inhibitor.
The FDA has approved the use of Janssen Biotech, Inc’s immunotherapy Darzalex in combination with pomalidomide and dexamethasone. Darzalex is used to treat multiple myeloma patients who have previously received at least 2 therapies with lenalidomide and a proteasome inhibitor.

In 2015, Darzalex was first approved as a monotherapy treatment for multiple myeloma patients who received at least 3 prior lines of therapy. Then in 2016, the drug received new FDA approvals to treat multiple myeloma patients with at least 1 prior therapy and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.

"Despite tremendous progress, most patients with multiple myeloma continually relapse or become resistant to available therapies, such as [proteasome inhibitors] and immunomodulatory agents,” Ajai Chari, MD, an associate professor of medicine for the Multiple Myeloma Program and associate director of Clinical Research at Mount Sinai Hospital, said in a statement.

The FDA approved use of Darzalex in combination following the results of the phase 1b EQUULEUS study. The study included 103 multiple myeloma patients who had received a prior proteasome inhibitor and immunomodulatory agent. The participants then received 16 mg/kg of Darzalex with pomalidomide and low-dose dexamethasone. This treatment was continued until the disease progressed.

The data showed that Darzalex combined with pomalidomide and dexamethasone results in an overall response rate of 59.2%, with very good partial response in 28.2% of patients, complete response in 5.8%, stringent complete response in 7.8%, and partial response was achieved in 17.5% of patients.

 "The recent approval of Darzalex is significant for patients and clinicians who urgently need new options and regimens,” said Peter F. Lebowitz, MD, PhD, from the Global Oncology Head at Janssen Research & Development, LLC. “This milestone underscores the versatility of Darzalex with a range of treatment regimens. We look forward to continued study of daratumumab in earlier stages of multiple myeloma and other cancers."

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up